NCT06274879View on ClinicalTrials.gov

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
Bile Duct Cancer
Interventions
DRUG

Gemcitabin, Cisplatin and Durvalumab

CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.

PROCEDURE

Biliary Radiofrequency Ablation

Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks

PROCEDURE

Endoscopic Retrograde Cholangio-Pancreatography with stenting

ERCP with stenting are applied at baseline and as clinically indicated

Trial Locations (1)

3010

Inselspital Bern University Hospital, Bern

All Listed Sponsors
collaborator

Swiss Cancer League

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER